Secondary Logo

Journal Logo

Symposium - TRIP

Changing paradigms of anti-VEGF in the Indian scenario

Shanmugam, P Mahesh

Author Information
Indian Journal of Ophthalmology: January 2014 - Volume 62 - Issue 1 - p 88-92
doi: 10.4103/0301-4738.126189
  • Open

Abstract

Since their introduction into ophthalmology, anti-vascular endothelial growth factors (anti-VEGF) have revolutionized the treatment of many retinal diseases. Anti-VEGF agents were introduced in India around 8 years back and much has been learnt from collective experience across continents resulting in change in treatment protocols, diseases treated, case selection and complications.

Use of anti-VEGF agents in the Indian Scenario present some unique challenges resulting in indigenous improvisations, modified protocols and treatment outcomes. This article aims to summarize the use of anti-VEGF agents in the Indian scenario by reviewing literature published on anti-VEGF agents from India, part of the information gained from surveys of vitreo-retinal surgeons in India and perceived opinion of the author.

Materials and Methods

A PubMed () search was performed individually using the keywords pegaptanib, bevacizumab and ranibizumab. The listed articles were screened manually for publications originating from India and these were grouped based on the disease treated, agents used, date of publication and the type of publication. Attempt was made to identify any change in paradigms of treatment, such as diseases treated and modification of treatment protocols over the time frame of the articles that have been published. The articles have been grouped under disease categories as listed below:

  1. Age-related macular degeneration (AMD)
  2. Diabetic retinopathy
  3. Retinal venous occlusions
  4. Choroidal neovascular membranes (CNVM) of other etiology
  5. Other ocular conditions
  6. Safety and complications and
  7. Miscellaneous articles

Retina practice trends study (www.retina-practice-trends.com) was a study performed amongst practicing vitreo-retinal specialists of India by a web-based questionnaire consisting of 80 questions under 7 sub-groups. One of the sub-groups was on the use of anti-VEGFs and information from the survey has also been perused.

Dr. Abishek Kothari performed Retnet Avastin Survey amongst the members of the retnet group (http://groups.yahoo.com/group.RetNetIndia) studying the bevacizumab usage preferences amongst Indian vitreo-retinal specialists and data from this has also been perused. Around 113-150 members of the vitreo-retinal community in India answered both the surveys.

Results

Publications by Indian based authors on anti-VEGF agents started in the year 2007, with 69 peer reviewed papers published until September 2013.[123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869] The years between 2007-10, being populated largely by case reports and occasional case series detailing the use of anti-VEGF agents in treating CNVM of other etiology, and retinopathy of prematurity[41] (2007), AMD[3] and adjunct to trabeculectomy[44] (2008). We can see a trend towards randomized case-control studies comparing different anti-VEGF agents, the use of combination treatments in AMD and other diseases since 2011 onwards.

Injection preferences and practices

In regards to the choice of anti-VEGF agent, bevacizumab is likely to be the most often used agent considering the economic burden of using ranibizumab in the developing economy of India. The lack of government aided and/or poor penetration of health insurance in the country also aid to the wide use of bevacizumab. As is the worldwide trend, pegaptanib is used seldom in India. The economic reasons also dictate the dosing pattern that is followed by most, which is loading dose of 3 monthly injections followed by pro re nata (PRN) dosing for AMD and only PRN dosing for most other indications.

Use of topical antibiotics with intravitreal anti-VEGF injections

Sixty-two percent of vitreo-retinal specialists use topical antibiotic before and after intravitreal injection wheras 27.4% use it only after injection (www.retina-practice-trends.com). The trend however is to use pre- and post-injection povidone iodine (5%) in the conjunctival cul-de-sac and avoid usage of pre- and post-injection antibiotics to eliminate emergence of drug-resistant organisms.

Method of fractionating bevacizumab

Using a single vial for multiple withdrawals seems to be the most common method followed by most vitreo-retinal specialists in India. Institutional users with access to a laminar flow hood tend to fractionate bevacizumab into multiple single use syringes or ampoules, the other method being patient pooling and dispensing a single vial on a single day. An opened vial or aliquots are stored most often up to a month and less commonly up to 2 weeks (http://groups.yahoo.com/group.RetNetIndia). The paucity of compounding pharmacies in India and lack of access to a laminar flow hood has resulted in the practice of multiple use vials. Velpandian et al. documenting safety of preparing aliquots of bevacizumab in pharmacy laboratory in one study, noted the low incidence of endophthalmitis if aliquots were prepared under controlled conditions and strict protocol.[1]

Indian vitreo-retinal specialists have reported endophthalmitis with all methods of fractionation, but in the absence of a controlled randomized study, it is improper to draw conclusions based on the survey alone (http://groups.yahoo.com/group.RetNetIndia).

Administration of the injection

Most tend to inject in the operating room after scrub and donning a sterile dress. A small percentage administers the injections in the side rooms of the operating theater complex and fewer still in the outpatient clinics (http://groups.yahoo.com/group.RetNetIndia).

We shall now look at individual disease entities.

Age-related macular degeneration

Azad et al. were the first to publish the results of bevacizumab for treating wet AMD in the Indian population in 2008 documenting improved vision in all AMD lesion types.[3] In this interventional case series, mean vision improved from 20/160 to 20/100 over 6 months, decrease in central macular thickness and lesion size, and 15 letter improvement of vision in 20% of treated patients, small lesions showing better improvement than large ones.[3]

One of the drawbacks of anti-VEGF therapy is the need for repeated injections. One of the ways to decrease the number of injections is by combining photodynamic therapy (PDT) with anti-VEGF injections. Mont Blanc and Everest studies found that the efficacy of the combination was similar to that of anti-VEGF montherapy.[7071] Kumar et al. in India addressed this issue, which however was not a comparative study.[5] Over 6 month follow-up, only 11.76% of the 17 treated eyes needed retreatment in this study with stabilization of vision (gain/loss < 2 lines) in 82.24% and improvement in 17.65% of the treated eyes. These results mirror other reports indicating that number of retreatments decrease with combination of PDT and anti-VEGF, the efficacy however being similar to anti-VEGF monotherapy.[5]

Biswas et al. in their study of 104 eyes found that visual and anatomical outcomes were similar with bevacizumab and ranibizumab, akin to the results of the CATT and IVAN trials.[117273]

There are no published studies from India on the impact of dosing patterns but the Retina practice trends (RPT) study revealed that most vitreo-retinal specialists would use 3 loading doses of bevacizumab or ranibizumab for AMD followed by PRN dosing based on optical coherence tomography (OCT) findings (www.retina-practice-trends.com). I perceive a move towards treat and extend protocol by most in India but the economic implications may limit the widespread use of the same.

The popularity of combined photodynamic therapy with anti-VEGF injections has also waned with the results of anti-VEGF monotherapy being similar to that of the combination therapy, while the economic burden of the combination is much higher given the added cost of the expensive photodynamic therapy.

To summarize, in regards to the use of anti-VEGF for AMD in India, most would use bevacizumab monotherapy on a loading dose followed by PRN dosing. Ranibizumab may be preferred in affordable patients and in poor-responders/those developing tachyphylaxis to bevacizumab. Combination treatments are used seldom to treat wet AMD but more often to treat polypoidal choroidal vasculopathy (PCV).

Diabetic retinopathy

Ghosh et al. have published one of the few comparative studies by Indian authors in the treatment of diabetic macular edema. This cross-sectional study compared macular thickness and posterior hyaloid changes after intravitreal bevacizumab in 15 patients and triamcinolone in 10 patients with no significant difference between the same.[16] Significant changes in posterior vitreous detachment occurred in both groups but this was accompanied by decreased central macular thickness, only in the intravitreal bevacizumab group.[16]

Studies have shown that frequent repetitive anti-VEGF injections with or without deferred laser photocoagulation achieve the best visual results in the treatment of diabetic macular edema (DME).[74] Translating it to the Indian scenario, though anti-VEGF agents are used as the initial treatment of fovea involving diabetic macular edema, they are seldom used in isolation but almost always with subsequent laser photocoagulation. Anti-VEGF agents are primarily used on a PRN basis in the treatment of DME. Triamcinolone as an alternative is used in pseudophakic patients who are non-responders to anti-VEGF agents and for economic considerations.

Gupta et al. documented the use of a single injection bevacizumab prior to diabetic vitrectomy decreasing the risk of post-operative recurrent vitreous hemorrhage.[17] This retrospective chart review showed that visual improvement at 6 months was noted in 74.5% patients treated with pre-operative bevacizumab vs. 52.9% untreated patients. Recurrent vitreous hemorrhage was also noted less often in bevacizumab pre-treated patients (6.4% vs. 16.1%).[17] However, the RPT survey showed that pre-operative anti-VEGF agent is not used routinely prior to vitrectomy in India by most surgeons, but for complicated vascular proliferations with high risk of intra-operative hemorrhage (www.retina-practice-trends.com).

Vein occlusions

A randomized controlled trial comparing grid laser, single/3 injections of ranibizumab + 1 session grid laser in the treatment of branch retinal vein occlusion by Azad et al. showed that the ranibizumab with laser groups to show better improvement than only laser group.[20] In a study of 30 patients, with branch retinal vein occlusion of at least 6 weeks duration that were randomized to grid laser alone and single/3 monthly intravitreal injections of ranibizumab (0.5 mg/0.05 ml) followed by grid laser treatment on 7th day after the first injection, they noted >3 line improvement at 6 months most often in the ranibizumab + laser groups.[20] The authors recommend the use of a single injection of ranibizumab followed by a single session of laser photocoagulation to treat macular edema associated with branch retinal vein occlusion.

In practice, it is perceived that anti-VEGFs form the mainstay in treating macular edema secondary to retinal vein occlusions, the injections being administered on a PRN basis. Grid and focal laser therapy after resolution of the retinal hemorrhages is often added to the treatment protocol, with some surgeons resorting to a sectorial laser photocoagulation directed at the areas of capillary non-perfusion in an attempt to decrease VEGF levels, thereby the number of injections.

Other CNVM

Case reports documenting the use of bevacizumab, ranibizumab and combination treatments such as anti-VEGF agents with photodynamic therapy have been published from India for the following indications:[222324252627282930313233343536373839]

Choroidal neovascularization associated with:

  1. Parafoveal telangiectasia type 2A (PFT)
  2. Myopia
  3. Angioid streaks
  4. Choroidal osteoma
  5. Best's vitelliform degeneration
  6. Traumatic choroidal rupture
  7. Toxoplasma scar
  8. Bietti's crystalline dystrophy.

A prospective and one retrospective case series documenting the use of anti-VEGF monotherapy or in combination with photodynamic therapy in the treatment of pathologic myopia and a retrospective case series documenting anti-VEGF to treat choroidal neovascularization associated with parafoveal telangiectasia have been published.[222324252627282930] In a noncomparative, consecutive, interventional case series, Mandal et al. showed that intravitreal bevacizumab resulted in > 3 line vision improvement in 75% of patients with myopic CNVM.[27] A retrospective comparison between PDT alone vs. PDT + triamcinolone vs. reduced fluence PDT + ranibizumab/bevacizumab to treat myopic CNVM showed visual improvement in all groups at 6 months, particularly in those treated with combination of PDT + anti-VEGF.[24]

A retrospective chart review of 16 eyes with PFT type IIA related CNVM treated with a mean 1.9 injections ranibizumab/bevacizumab over 1 year showed significant visual improvement.[23] Benefit of anti-VEGF to treat parafoveal telangiectasia without CNVM is however limited and temporary and is not advised.

Essentially, CNVM of other etiology are primarily being treated with PRN anti-VEGF agents with the combination of anti-VEGF and PDT having a limited role.

Other retinal disorders

One case report by Indian authors documents the use of anti-VEGF to treat aggressive posterior retinopathy of prematurity and the RPT survey indicated that 43% of the retinal specialists were not averse to using bevacizumab in infants (www.retina-practice-trends.com).[43] However, laser photocoagulation remains the primary treatment option in managing retinopathy of prematurity (ROP), with select situations such as progression despite adequate laser photocoagulation, undilating pupil due to iris vascular engorgement being treated with half-dose of intravitreal anti-VEGF agents.

Indian authors have documented anti-VEGF use in the following conditions:[4445464748495051525354555657]

  1. Subconjunctival bevacizumab vs. mitomycin C as an adjunct to trabeculectomy (randomized controlled trial and case series)
  2. Subconjunctival bevacizumab for advanced pterygium (case report)
  3. Intracameral bevacizumab as an adjunct to trabeculectomy in neovascular glaucoma (case series)
  4. Topical and subconjunctival bevacizumab to treat corneal neovascularization (case reports)
  5. Intravitreal bevacizumab to treat Coats disease (case reports)
  6. Rubeosis iridis (case report)
  7. Anterior chamber neovascular membrane in blind eye (case report)
  8. Circumscribed choroidal hemangioma (case reports)

Conclusion

Akin to international trends, anti-VEGF agents have become the primary mode of therapy for many retinal diseases in India. Anti-VEGF monotherapy is used to treat CNVM secondary to AMD and other etiology, however on a PRN basis and combination of anti-VEGF and laser photocoagulation is used to treat macular edema in diabetic retinopathy and retinal vein occlusions.

Data on the systemic and ocular safety of the anti-VEGF agents in the Indian scenario is sparse and focused surveys aimed at these issues may help us devise treatment algorithms suited to our population.

References

1. Velpandian T, Sharma C, Garg SP, Mandal S, Ghose S. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries Indian J Ophthalmol. 2007;55:488–90
2. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Indian J Ophthalmol. 2011;5:191–6
3. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population Jpn J Ophthalmol. 2008;52:52–6
4. Rishi P, Sen PR, Shroff D, Chhablani J. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient Indian J Ophthalmol. 2008;56:438–9
5. Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: A pilot study Retina. 2008;28:1296–301
6. Pai SA, Shetty R. Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy Acta Ophthalmol. 2009;87:806–7
7. Chawla S, Misra V, Khemchandani M. Pneumatic displacement and intravitreal bevacizumab: A new approach for management of submacular hemorrhage in choroidal neovascular membrane Indian J Ophthalmol. 2009;57:155–7
8. Agarwal M, Chaudhary SP, Narula R, Rajpal S. Pneumatic displacement and intravitreal bevacizumab for management of submacular hemorrhage in choroidal neovascular membrane Indian J Ophthalmol. 2010;58:170–1
9. Chhablani JK. Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration Oman J Ophthalmol. 2010;3:99–100
10. Sahu AK, Narayanan R. Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation Retina. 2010;30:981
11. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparing ranibizumab with bevacizumab Ophthalmology. 2011;118:600–600.e2
12. Singh B, Narayanan R. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration Retina. 2012;32:206–7
13. Bansal AG, Narayanan R, Majji AB, Thomas R. Neovascular changes after pegaptanib in diabetics Ophthalmology. 2007;114:615–6
14. Kumar V, Ghosh B, Raina UK, Goel N. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema Am J Ophthalmol. 2008;146:974
15. Kumar V, Ghosh B, Raina UK, Goel N. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema (comment) Acta Ophthalmol. 2010;88:e3
16. Ghosh S, Dutta J, Mukhopadhyay S, Bhaduri G. Correlation of macular thickness and posterior hyaloid change following bevacizumab and triamcinolone in diffuse diabetic macular edema in middle-aged patients Int Ophthalmol. 2011;31:363–8
17. Gupta A, Bansal R, Gupta V, Dogra MR. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab Int Ophthalmol. 2012;32:135–44
18. Sharma A, Madhusudhan RJ, Nadahalli V, Damgude SA, Sundaramoorthy SK. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report Indian J Ophthalmol. 2012;60:234–5
19. Shroff D, Bhargava A, Sharma B, Gupta C, Shroff C. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion Graefes Arch Clin Exp Ophthalmol. 2010;248:1203
20. Azad R, Vivek K, Sharma Y, Chandra P, Sain S, Venkataraman A. Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion Indian J Ophthalmol. 2012;60:263–6
21. Verma L, Chakravarti A, Gupta A, Prakash S. One day wonder: Fast resolution of macular edema following intravitreal ranibizumab in retinal venous occlusions Indian J Ophthalmol. 2013;61:528–30
22. Shanmugam MP, Mythri HM, Shetty NS. Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane Indian J Ophthalmol. 2007;55:490–1
23. Narayanan R, Chhablani J, Sinha M, Dave V, Tyagi M, Pappuru RR, et al Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2 Retina. 2012;32:2001–5
24. Rishi P, Rishi E, Shroff D. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia Indian J Ophthalmol. 2009;57:241–2
25. Dave V, Chhablani J, Narayanan R. Different treatment modalities for choroidal neovascularization in two eyes of one patient with bilateral type 2A parafoveal telangiectasia Indian J Ophthalmol. 2013;61:353–5
26. Rishi P, Shroff D, Rishi E. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia Graefes Arch Clin Exp Ophthalmol. 2008;246:619–21
27. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization Eur J Ophthalmol. 2007;17:620–6
28. Dave V, Narayanan R. Choroidal neovascularization in pathologic myopia (comment) Am J Ophthalmol. 2010;150:752–3
29. Rishi P, Rishi E, Venkataraman A, Gopal L, Sharma T, Bhende M, et al Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia Indian J Ophthalmol. 2011;59:242–6
30. Prabhu VV, Morris RJ, Shah PK, Narendran V. Combination treatment of low fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane secondary to angioid streaks in Paget's disease-12 month results Indian J Ophthalmol. 2011;59:306–8
31. Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks Indian J Ophthalmol. 2007;55:457–8
32. Narayanan R, Shah VA. Intravitreal bevacizumab in the management of choroidal neovascular membrane secondary to choroidal osteoma Eur J Ophthalmol. 2008;18:466–8
33. Rishi E, Rishi P, Mahajan S. Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy Indian J Ophthalmol. 2010;58:160–2
34. Chhablani J, Jalali S. Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child Eur J Ophthalmol. 2012;22:677–9
35. Mandal S, Sinha S, Venkatesh P, Vashisht N. Intravitreal bevacizumab in choroidal neovascularization associated with Best's vitelliform dystrophy Indian J Ophthalmol. 2011;59:262–3
36. . Combination of photodynamic therapy with intravitreal bevacizumab for post-peribulbar anesthesia (penetrating trauma)-persistent choroidal neovascular membrane Indian J Ophthalmol. 2008;56:163–4
37. Nachiappan K, Krishnan T, Madhavan J. Ranibizumab for choroidal neovascular membrane in a rare case of Bietti's crystalline dystrophy: A case report Indian J Ophthalmol. 2012;60:207–9
38. Pandey N, Dwivedi V. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis Indian J Ophthalmol. 2013;61:86
39. Shah NJ, Shah UN. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis Indian J Ophthalmol. 2011;59:318–9
40. Rishi E, Rishi P, Ratra D, Bhende M. Off-label use of bevacizumab in retinopathy of prematurity Retina. 2009;29:284–5
41. Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity (comment) Indian J Ophthalmol. 2007;55:319
42. Sangtam T, Vinekar A, Maheshwar B, Dogra MR, Eong KG. Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity (comment) Indian J Ophthalmol. 2007;55:317–8
43. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity Indian J Ophthalmol. 2007;55:75–6
44. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study Ophthalmology. 2008;115:2141–5.e2
45. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma Eur J Ophthalmol. 2009;19:435–41
46. Sengupta S, Venkatesh R, Ravindran RD. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial J Glaucoma. 2012;21:450–9
47. Saxena S, Kishore P, Pandey S, Khattri M, Kumar D. Topical bevacizumab for corneal neovascularization after penetrating keratoplasty Eur J Ophthalmol. 2009;19:870–2
48. Kesarwani S, Sahu SK, Basu S. Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome J AAPOS. 2012;16:309–11
49. Raghuram A, Saravanan VR, Narendran V. Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye Indian J Ophthalmol. 2007;55:460–2
50. Agarwal M, Dubey S. Intra-cameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye (comment) Indian J Ophthalmol. 2008;56:258–9
51. Venkatesh P, Mandal S, Garg S. Management of Coats disease with bevacizumab in 2 patients Can J Ophthalmol. 2008;43:245–6
52. Rajagopal J, Kamath AG, Kamath GG, Rao MM. Intraocular injection of bevacizumab for rubeosis capsulare in a pseudophakic eye Eye (Lond). 2010;24:384
53. Chhablani JK, Narayanan R. Intravitreal bevacizumab injection for central serous chorioretinopathy (comment) Retina. 2010;30:1323–24
54. Mandal S, Naithani P, Venkatesh P, Garg S. Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma Indian J Ophthalmol. 2011;59:248–51
55. Singh N, Kulkarni P, Aggarwal AN, Rai Mittal B, Gupta N, Behera D, et al Choroidal metastasis as a presenting manifestation of lung cancer: A report of 3 cases and systematic review of the literature Medicine (Baltimore). 2012;91:179–94
56. Saxena S, Vishwkarma K, Khattri M, Kishore P. Multiple subconjunctival bevacizumab for advanced primary pterygium Ann Ophthalmol (Skokie). 2010;42(Spec No):28–30
57. Shukla D, Chakraborty S, Rajendran A. Combined pharmacotherapy and thermotherapy for chronic central serous chorioretinopathy with anterior segment neovascularisation Eye (Lond). 2008;22:600–2
58. Shah GY, Ambatipudi S, Fernandes M, Lakshmipathy M, Varma PV, Sachdeva V, et al We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office (comment) Retina. 2010;30:1325–6
59. Sinha S, Vashisht N, Venkatesh P, Garg SP. Managing bevacizumab-induced intraocular inflammation Indian J Ophthalmol. 2012;60:311–3
60. Kumar A, Sehra SV, Thirumalesh MB, Gogia V. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales’ disease Graefes Arch Clin Exp Ophthalmol. 2012;250:685–90
61. Subramanyam A, Phatak S, Chudgar D. Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment Indian J Ophthalmol. 2007;55:483–6
62. Rishi P, Kasinathan N, Sahu C. Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration Clin Ophthalmol. 2011;5:167–70
63. Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, et al Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema Doc Ophthalmol. 2008;116:129–35
64. Azad R, Chandra P, Gupta R. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration Indian J Ophthalmol. 2007;55:441–3
65. Nagpal M, Nagpal K, Nagpal PN. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin) Indian J Ophthalmol. 2007;55:437–9
66. Santhan Gopal KS. Off with the label and on the Avastin bandwagon: Why now and how far? Indian J Ophthalmol. 2009;57:253–6
67. Kumar A. Bevacizumab and macular edema (comment) Ophthalmology. 2007;114:1574–9.e1
68. Hussain N, Ghanekar Y, Kaur I. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice Indian J Ophthalmol. 2007;55:445–50
69. Shukla D, Namperumalsamy P, Goldbaum M, Cunningham ET Jr. Pegaptanib sodium for ocular vascular disease Indian J Ophthalmol. 2007;55:427–30
70. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, et al MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results Ophthalmology. 2012;119:992–1000
71. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al EVEREST study. Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina. 2012;32:1453–64
72. CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med. 2011;364:1897–908
73. IVAN Study Investigators. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial Ophthalmology. 2012;119:1399–411
74. Diabetic Retinopathy Clinical Research Network. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, et al Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment. Three-year randomized trial results Ophthalmology. 2012;119:2312–8

Source of Support: Nil.

Conflict of Interest: None declared.

Keywords:

Anti-VEGF; India; treatment protocols

© 2014 Indian Journal of Ophthalmology | Published by Wolters Kluwer – Medknow